Skip over navigation
The Hospital
Research
Support Us
Ottawa Hospital Research Institute
Home
Français
Directions & Maps
Contact Us
About Us
Vision and Strategic Directions
Board Chair and CEO Message
Leadership Team
Annual Reports
Facilities
Research Data Management
Equity, Diversity and Inclusion
Wellness
Our Research
Priorities, Programs and Diseases
Researcher Profiles
National Research Networks
Scientific Publications
Research Awards
Technology Transfer
Industry Sponsored Research
Responsible Innovation
For Students & Fellows
News & Events
Newsroom
Seminars & Events
Career Opportunities
For Patients
News & Events
Home
>
News & Events
>
Newsroom
Bookmark or Share
Display Options
Display Options
+
Increase
/
-
Decrease
font size
High contrast version
Printer-friendly version
Newsroom
Seminars & Events
Newsroom
Dr. Ian Lorimer investigates approaches for converting brain cancer stem cells into a more treatable form
August 30, 2013
Cancer researchers are looking at one of the most common cancer-associated genes in a totally new light, thanks to new research led by
Dr. Ian Lorimer
. Dr. Lorimer’s study concerns the PTEN gene, which is deleted in more than 90% of brain cancers, as well as in many other kinds of cancer. Dr. Lorimer found that loss of the PTEN gene leads to inactivation of a protein called Lgl1. This plays a key role in maintaining brain cancer cells in a stem cell-like state that is resistant to therapy. In the study, Dr. Lorimer also used several laboratory approaches to convert brain cancer stem cells from TOH patients into a less dangerous and more treatable form.
See
Oncotarget
for details.
Funders:
Canadian Institutes of Health Research, Ontario Ministry of Training, Colleges and Universities
Media contact
Jennifer Ganton
Director, Communications and Public Relations
Ottawa Hospital Research Institute
613-798-5555 ext. 73325
jganton@ohri.ca